Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 13, 2015 05:30 ET | Source: Nexvet Biopharma plc

Nexvet Reports Financial Results for Second Quarter of Fiscal Year 2015

DUBLIN, Ireland and MELBOURNE, Australia, March 13, 2015 (GLOBE NEWSWIRE) -- Veterinary biologic therapy developer Nexvet Biopharma (Nasdaq:NVET) today announced its financial results for the three...
March 09, 2015 05:30 ET | Source: Nexvet Biopharma plc

Nexvet Provides Update on Pivotal Field Safety and Efficacy Study for NV-01

DUBLIN, Ireland and MELBOURNE, Australia, March 9, 2015 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET), a veterinary biologic therapy developer, announced today an update on its pivotal field...
February 11, 2015 05:30 ET | Source: Nexvet Biopharma plc

Nexvet Biopharma Announces Closing of Initial Public Offering

DUBLIN, Ireland and MELBOURNE, Australia, Feb. 11, 2015 (GLOBE NEWSWIRE) -- Veterinary biologic therapy developer Nexvet Biopharma (Nasdaq:NVET) today announced the closing of its initial public...
February 05, 2015 05:30 ET | Source: Nexvet Biopharma plc

Nexvet Biopharma plc Announces Pricing of Initial Public Offering

DUBLIN, Ireland and MELBOURNE, Australia, Feb. 5, 2015 (GLOBE NEWSWIRE) -- Veterinary biologic therapy developer Nexvet Biopharma (Nasdaq:NVET) today announced the pricing of its initial public...
December 03, 2014 05:30 ET | Source: Nexvet Biopharma plc

Nexvet Announces Collaboration and Distribution Agreement With Virbac

DUBLIN, Ireland and MELBOURNE, Australia, Dec. 3, 2014 (GLOBE NEWSWIRE) -- Veterinary biologic therapy developer Nexvet Biopharma today announced the signing of a ten year collaboration and...
October 16, 2014 05:30 ET | Source: Nexvet Biopharma plc

Nexvet Initiates Pivotal Study for Canine Osteoarthritic Pain Therapy, NV-01

DUBLIN, Ireland and MELBOURNE, Australia, Oct. 16, 2014 (GLOBE NEWSWIRE) -- Veterinary biologic therapy developer Nexvet Biopharma today announced the initiation of a pivotal field efficacy and safety...